Candriam SCA’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Candriam SCA’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-67,551	Closed	-$8.89M	–	833
2020 Q4	$8.89M	Sell	67,551 -118,170	-64%	-$10.4M	0.07%	283
2020 Q3	$9.38M	Hold	185,721	–	–	0.09%	250
2020 Q2	$8.85M	Buy	185,721 +13,966	+8%	+$650K	0.09%	234
2020 Q1	$9.64M	Hold	171,755	–	–	0.11%	219
2019 Q4	$9.86M	Sell	171,755 -47,245	-22%	-$2.34M	0.11%	221
2019 Q3	$7.88M	Sell	219,000 -104,000	-32%	-$4.06M	0.1%	229
2019 Q2	$9.99M	Sell	323,000 -102,000	-24%	-$2.77M	0.12%	190
2019 Q1	$9.97M	Buy	425,000 +280,000	+193%	+$4.49M	0.13%	189
2018 Q4	$2M	Buy	+145,000	New	+$1.83M	0.03%	464

Candriam SCA's EIDX Position: Q1 2021 in Review

Candriam SCA sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 67,551 shares — an estimated $8.89M sold.

Candriam SCA first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $9.99M in Q2 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Candriam SCA reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Candriam SCA sold 67,551 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $8.89M.
Candriam SCA first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Candriam SCA's Eidos Therapeutics, Inc. Common Stock position peaked at $9.99M in Q2 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Candriam SCA's 13F filing for Q1 2021, filed 29 Apr 2021.